Gaurang Zala, MD
Family Medicine · San Antonio, TXNPI 1255541678
Payments from drug & device makers
Across 295 payments — averaging $15.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$709
- Novo Nordisk$602
- AstraZeneca$434
- Lilly USA, LLC$350
- Amgen$304
- Sanofi-aventis U.S. LLC$263
- plus $2K from 26 others
What the payments were for
- Food & beverage$4,43499%
- Education$291%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 43 | $709 |
| Novo Nordisk | 43 | $602 |
| AstraZeneca | 25 | $434 |
| Lilly USA, LLC | 28 | $350 |
| Amgen | 19 | $304 |
| Sanofi-aventis U.S. LLC | 20 | $263 |
| Boehringer Ingelheim | 16 | $252 |
| Merck | 18 | $238 |
| Exact Sciences | 13 | $223 |
| Pfizer | 17 | $208 |
| Otsuka America Pharmaceutical, Inc. | 7 | $166 |
| Abbott | 4 | $83 |
| Johnson & Johnson(2 entities) | 7 | $81 |
| AbbVie | 4 | $68 |
| Novartis | 4 | $61 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $61 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $46 |
| Corcept Therapeutics | 3 | $43 |
| E.r. Squibb & Sons, L.L.C. | 3 | $34 |
| Astellas Pharma US Inc | 1 | $28 |
| Inspire Medical Systems, Inc. | 1 | $27 |
| Phadia US Inc. | 2 | $23 |
| Axsome Therapeutics, Inc. | 1 | $21 |
| Shield Therapeutics Inc | 1 | $21 |
| Esperion Therapeutics, Inc. | 1 | $20 |
| Daiichi Sankyo Inc. | 1 | $18 |
| Bayer | 1 | $16 |
| Sanofi Pasteur Inc. | 1 | $14 |
| Amarin Pharma, Inc. | 1 | $14 |
| Idorsia Pharmaceuticals US Inc | 1 | $13 |
| Assertio Therapeutics, Inc. | 1 | $12 |
| Hikma Pharmaceuticals USA | 1 | $11 |
How this compares
$4,463 in reported general payments places this provider in the 80th percentile of 8,760 family medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 162 | $244,737 |
| MounjaroTirzepatide | 170 | $177,209 |
| FarxigaDapagliflozin Propanediol | 117 | $141,223 |
| EliquisApixaban | 100 | $90,914 |
| JardianceEmpagliflozin | 70 | $75,168 |
| RybelsusSemaglutide | 40 | $69,075 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 57 | $58,226 |
| TrulicityDulaglutide | 23 | $39,723 |
| EntrestoSacubitril/Valsartan | 31 | $38,206 |
| Tresiba Flextouch U-200Insulin Degludec | 32 | $34,249 |
| TradjentaLinagliptin | 30 | $30,116 |
| LinzessLinaclotide | 20 | $29,822 |
| ProliaDenosumab | 15 | $25,765 |
| JanuviaSitagliptin Phosphate | 24 | $22,843 |
| XareltoRivaroxaban | 13 | $16,262 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $602 | $313,812202 claims |
| Lilly USA, LLCMounjaro, Trulicity | $350 | $216,932193 claims |
| AstraZenecaFarxiga, Symbicort | $434 | $145,973136 claims |
| Boehringer IngelheimJardiance, Tradjenta | $252 | $105,284100 claims |
| PfizerEliquis, Paxlovid | $208 | $93,633111 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta | $709 | $87,63195 claims |
| NovartisEntresto | $61 | $38,20631 claims |
| AbbVieLinzess | $68 | $29,82220 claims |
| AmgenProlia | $304 | $25,76515 claims |
| MerckJanuvia | $238 | $22,84324 claims |
| Johnson & JohnsonXarelto | $81 | $16,26213 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 8,760 family medicine providers in Texas.
Other family medicine in San Antonio
- Douglas DenhamSan Antonio$68.5M
- George AtieeSan Antonio$19.9M
- Leonel ReyesSan Antonio$4.3M
- Brian MacgillivraySan Antonio$3.2M
- Juan GarzaSan Antonio$2.5M
- Vicki MillerPasadena$58.3M
- Hareshkumar BogharaDesoto$30.3M
- Earl MartinTomball$30.1M
- Lisa HollowayHouston$30.1M
- William SegerFort Worth$27.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.